Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior

Hum Pathol. 2013 Nov;44(11):2400-9. doi: 10.1016/j.humpath.2013.05.020. Epub 2013 Sep 2.

Abstract

The purpose of this retrospective study was to investigate the role of galectin-3 (LGALS3) expression in predicting the recurrence and the progression potential of prolactin (PRL) and adrenocorticotropic hormone (ACTH)-producing pituitary adenomas and its correlation with the RUNX1 and RUNX2 transcription factors involved in the regulation mechanism of LGALS3 expression. Clinical, neuroradiologic, and follow-up data from 92 pituitary adenomas, including 59 PRL cell adenomas and 33 ACTH-functioning pituitary adenomas, were collected. The LGALS3 expression was analyzed by both immunohistochemistry and quantitative real time-polymerase chain reaction, whereas RUNX1 and RUNX2 were analyzed by quantitative real time-polymerase chain reaction only. The data obtained indicated that invasive growth with suprasellar extension, Ki-67 labeling index, and LGALS3 immunohistochemical and/or LGALS3 messenger RNA levels are the most important histologic features for assessing a high risk of progression or recurrence of PRL- and ACTH-functioning pituitary adenomas. Multivariate Cox regression analysis assessed LGALS3 immunohistochemical positivity in at least 30% of neoplastic cells and/or LGALS3 messenger RNA positivity (P < .001) as strong predictive factors of recurrence/tumor progression followed by a Ki-67 labeling index greater than 3% (P = .019) in the 81 cases in which follow-up data were available. In addition, a significant correlation between LGALS3 and RUNX1 expression levels (P = .0435) was found. This retrospective immunohistochemical and molecular study demonstrated that LGALS3 expression appeared to be a predictive factor of the aggressive behavior of PRL- and ACTH-functioning pituitary adenomas, and its expression was correlated with RUNX1 expression levels.

Keywords: ACTH; Ct; FSH; GH; Galectin-3; HPF; IHC; LGALS3; LH; LI; MRI; PA; PRL; Pituitary adenoma; Prognosis; ROC; RUNX1; RUNX2; TSH; adrenocorticotropin; cycle threshold; follicle-stimulating hormone; galectin-3; growth hormone; high-power field; immunnohistochemistry; labeling index; luteinizing hormone; magnetic resonance imaging; pituitary adenoma; prolactin; qRT-PCR; quantitative real time-polymerase chain reaction; receive operating characteristic; thyrotropin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoma / metabolism
  • Adenoma / pathology*
  • Adolescent
  • Adrenocorticotropic Hormone / metabolism
  • Adult
  • Aged
  • Biomarkers, Tumor / metabolism*
  • Blood Proteins
  • Child
  • Core Binding Factor Alpha 1 Subunit / metabolism
  • Core Binding Factor Alpha 2 Subunit / metabolism
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Galectin 3 / genetics
  • Galectin 3 / metabolism*
  • Galectins
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / metabolism
  • Neoplasm Recurrence, Local / pathology*
  • Pituitary Neoplasms / metabolism
  • Pituitary Neoplasms / pathology*
  • Prognosis
  • Prolactin / genetics
  • Prolactinoma / metabolism*
  • Retrospective Studies
  • Young Adult

Substances

  • Biomarkers, Tumor
  • Blood Proteins
  • Core Binding Factor Alpha 1 Subunit
  • Core Binding Factor Alpha 2 Subunit
  • Galectin 3
  • Galectins
  • LGALS3 protein, human
  • RUNX1 protein, human
  • RUNX2 protein, human
  • Adrenocorticotropic Hormone
  • Prolactin